Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Agonists: Mixed-Action Agents01:28

Adrenergic Agonists: Mixed-Action Agents

Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adherence to Stillbirth Guidelines and Women's Psychological Well-Being: The CLASS (CiaoLApo Stillbirth Support) Cross-Sectional Study.

Birth (Berkeley, Calif.)·2026
Same author

The impact of childhood sexual and physical abuse on needs for care among people with first episode psychosis.

Child abuse & neglect·2025
Same author

The LISTEN (Lactation Support afTer pEriNatal loss) Project: Pathways of Loss and Lactation Care in Italy.

Journal of midwifery & women's health·2025
Same author

Management of Subsequent Pregnancy After Perinatal Death: Results from the UNSURENESS Study.

Journal of clinical medicine·2025
Same author

Small hands, big ideas: exploring nurturing care through Beatrice Alemagna's 'What is a Child?'

Medical humanities·2025
Same author

Assessment of the psychometric properties of the Italian version of the revised impact of miscarriage scale (RIMS): a validity and reliability study.

BMC pregnancy and childbirth·2025

Related Experiment Video

Updated: Jun 26, 2026

An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

Amphetamine derivatives and obesity.

Valdo Ricca1, Giovanni Castellini, Edoardo Mannucci

  • 1Psychiatric Unit, Department of Neuropsychiatric Sciences, Florence University, Viale Morgagni 85, 50134 Firenze, Italy. valdo.ricca@unifi.it

Appetite
|December 24, 2008
PubMed
Summary

Obese patients seeking weight loss often use amphetamine derivatives. This use is linked to greater eating disorder symptoms and more severe obesity, despite no difference in anxiety or depression.

More Related Videos

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study
03:05

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study

Published on: November 21, 2025

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Related Experiment Videos

Last Updated: Jun 26, 2026

An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study
03:05

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study

Published on: November 21, 2025

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Area of Science:

  • Psychiatry
  • Clinical Psychology
  • Obesity Medicine

Background:

  • Amphetamine derivatives are sometimes used for weight loss.
  • Understanding the psychopathological and clinical profiles of users is crucial for effective treatment.

Purpose of the Study:

  • To investigate the features of overweight/obese subjects with and without a history of amphetamine derivative consumption.
  • To compare psychopathological and clinical characteristics between these two groups.

Main Methods:

  • A consecutive series of 451 overweight/obese subjects were assessed.
  • Utilized Structured Clinical Interview for DSM-IV, Eating Disorder Examination questionnaire (EDE-Q), Binge Eating Scale (BES), Beck Depression Inventory (BDI), and Spielberg's State-Trait Anxiety Inventory (STAI).

Main Results:

  • 136 participants (30.1%) reported prior amphetamine derivative use.
  • Amphetamine users had higher BMI, childhood overweight history, and elevated scores on EDE-Q and BES.
  • No significant differences were found in depression (BDI) or anxiety (STAI) scores between groups.

Conclusions:

  • Amphetamine derivatives are frequently used by obese patients pursuing weight loss.
  • Consumption is associated with increased eating psychopathology and more severe obesity.
  • Further research into the long-term effects and clinical implications is warranted.